J.Kumar Infraprojects, 17 %Upside Call & Research Report by Institutional Research at HDFC Securities.Analyst : Mr. Parikshit D KandpalReport Date: 11 February 2021CMP Rs. 188 Target price Rs. 220 J.Kumar Infraprojects (Q3FY21 Results Review Report) Execution recovery leads to beat. Maintain BUY J Kumar (JKIL) reported revenue/EBITDA/PAT at Rs 8.1/1.2/0.45bn, beating our estimate by 21/7/12% […]
Read more..Endurance Technologies, 13 %Upside Call & Research Report by Institutional Research at HDFC Securities. Analyst : Mr. Aditya Makharia Report Date: 11 February 2021 CMP Rs. 1483 Target price Rs. 1680 Endurance Technologies (Q3FY21 Results Review Report) Import substitution to drive outperformance. BUY 3Q revenues (+24% YoY/15% QoQ) and margins at 17.3% were above estimates […]
Read more..GAIL (India) , 14 %Upside Call & Research Report by Institutional Research at HDFC Securities. Analysts : Mr. Harshad Katkar,Mr. Nilesh Ghuge Report Date: 12 February 2021 CMP Rs. 134 Target price Rs. 153 GAIL (India) (Q3FY21 Results Review Report) Capacity utilisations meet normalcy. BUY Our BUY recommendation on GAIL with a price target of […]
Read more..Indraprastha Gas , 6 %Upside Call & Research Report by Institutional Research at HDFC Securities. Analysts : Mr. Harshad Katkar,Mr. Nilesh Ghuge Report Date: 12 February 2021 CMP Rs. 557 Target price Rs. 588 Indraprastha Gas (Q3FY21 Results Review Report) Muted performance. ADD Our ADD recommendation on Indraprastha Gas with a target price of INR […]
Read more..TTK Prestige , 13 %Upside Call & Research Report by Institutional Research at HDFC Securities. Analyst : Mr. Naveen Trivedi Report Date: 12 February 2021 CMP Rs. 6933 Target price Rs. 7850 TTK Prestige (Q3FY21 Results Review Report) Broad-based recovery, improving earnings visibility. Maintain ADD TTK delivered a stellar performance as revenue/EBITDA grew by 24/42% […]
Read more..Aurobindo Pharma , 16 %Upside Call & Research Report by Institutional Research at HDFC Securities. Analyst : Ms. Bansi Desai Report Date: 12 February 2021 CMP Rs. 935 Target price Rs. 1080 Aurobindo Pharma (Q3FY21 Results Review Report) Steady quarter, outlook remains strong. Maintain BUY Q3 revenue/PAT grew by 8%/17% YoY, in line with estimates. […]
Read more..ITC ltd , 8 %Upside Call & Research Report by Institutional Research at HDFC Securities.Analysts: Mr. Varun Lohchab & Mr. Naveen TrivediReport Date: 12 February 2021CMP Rs. 226 Target price Rs. 245 ITC (Q3FY21 Results Review Report) In-line show; FMCG continues to shine. Maintain BUY ITC’s 3QFY21 was broadly in line as the company saw […]
Read more..Heidelberg Cement, 17%Upside Call & Research Report by Institutional Research at HDFC Securities.Analyst: Ms. Rajesh RaviReport Date: 12 February 2021CMP Rs. 228 Target price Rs. 266 (Q3FY21 Results Review Report) Major maintenance work inflated opex during 3Q. Maintain BUY Heidelberg Cement’s (HEIM) 3QFY21 revenue grew by 9% YoY to INR 5.95bn led by both higher sales […]
Read more..BSE , 16%Upside Call & Research Report by Institutional Research at HDFC Securities. Analyst: Mr. Mr. Amit Chandra Report Date: 12 February 2021 CMP Rs. 603 Target price Rs. 700 BSE (Q3FY21 Results Review Report) Taking steps to accelerate growth. Maintain BUY BSE revenue declined 3.8% QoQ due to lower market-linked revenue (core transaction and […]
Read more..Ajanta Pharma , 29%Upside Call & Research Report by Institutional Research at HDFC Securities. Analyst: Mr. Krishnan ASV Report Date: 3 February 2021 CMP Rs. 1747 Target price Rs. 2250 Ajanta Pharma (Q3FY21 Results Review) Poised to re-rate. Maintain BUY Ajanta’s Q3 revenue grew by 15% YoY driven by strong performance in branded markets and […]
Read more..